| scholarly article | Q13442814 |
| P50 | author | Jonathan Graff-Radford | Q83230600 |
| Maria Vassilaki | Q89840092 | ||
| Prashanthi Vemuri | Q90060450 | ||
| Yonas E Geda | Q91669167 | ||
| Val J. Lowe | Q107200019 | ||
| Mary M Machulda | Q107207938 | ||
| Rosebud O Roberts | Q107215009 | ||
| Jeremiah A Aakre | Q114336659 | ||
| Jeremy A Syrjanen | Q114336736 | ||
| Clifford Jack | Q30505709 | ||
| Ronald C. Petersen | Q56839853 | ||
| Michelle M Mielke | Q60909929 | ||
| David S Knopman | Q63967707 | ||
| P2093 | author name string | Walter K Kremers | |
| P2860 | cites work | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers | Q26745508 | ||
| The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 | ||
| Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 | ||
| Mild cognitive impairment as a diagnostic entity | Q29619568 | ||
| Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis | Q30235369 | ||
| Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria | Q30458193 | ||
| Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system | Q30577777 | ||
| The Alzheimer's disease neuroimaging initiative | Q31030939 | ||
| Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration | Q33581412 | ||
| The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics | Q33650976 | ||
| Validation of the telephone interview for cognitive status-modified in subjects with normal cognition, mild cognitive impairment, or dementia | Q33802235 | ||
| Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging | Q34125565 | ||
| History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population | Q34314700 | ||
| Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. | Q34940642 | ||
| Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study | Q35073049 | ||
| Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression | Q35106472 | ||
| Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly | Q35119419 | ||
| The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging | Q35758628 | ||
| Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis | Q35800785 | ||
| Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis | Q35896890 | ||
| Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings | Q36305487 | ||
| An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease | Q36650399 | ||
| Mild cognitive impairment due to Alzheimer disease in the community | Q37245465 | ||
| Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study | Q37524511 | ||
| A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity | Q37533514 | ||
| Defining imaging biomarker cut points for brain aging and Alzheimer's disease | Q38803637 | ||
| Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia | Q40649206 | ||
| Advances in strategies for minimizing and adjusting for survey nonresponse | Q40923269 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 2039-2048 | |
| P577 | publication date | 2017-10-13 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers | |
| P478 | volume | 89 |
| Q88475507 | Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality |
| Q90060454 | Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging |
| Q92843396 | Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia |
| Q90646389 | Cerebral microbleeds: Prevalence and relationship to amyloid burden |
| Q89104140 | Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification |
| Q90304162 | Predicting Progression to Mild Cognitive Impairment |
| Q91882184 | Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework |
| Q49990629 | Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly |
Search more.